Comparative Pharmacology
Head-to-head clinical analysis: ERYTHROMYCIN STEARATE versus PEDIAMYCIN 400.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYTHROMYCIN STEARATE versus PEDIAMYCIN 400.
ERYTHROMYCIN STEARATE vs PEDIAMYCIN 400
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation of peptides.
Erythromycin binds to the 50S subunit of the bacterial ribosome and inhibits protein synthesis by blocking the translocation step.
250-500 mg orally every 6 hours or 500-1000 mg orally every 12 hours; maximum 4 g/day.
400 mg orally every 6 hours for 10 days.
None Documented
None Documented
1.4-2 hours in adults with normal renal function; prolonged to 5-6 hours in anuria; unchanged in hepatic impairment.
1.5-2 hours; prolonged in renal impairment (up to 6 hours)
Primarily excreted in bile as active drug; about 2-5% excreted renally as unchanged drug. Up to 15% excreted in feces.
Renal (80-90% unchanged); biliary/fecal (minor, <5%)
Category A/B
Category C
Macrolide Antibiotic
Macrolide Antibiotic